A-Med Health Care has sold its Specialty Pharmacy Division to Altamont Capital Partners
A-Med Health Care has sold its Specialty Pharmacy Division to Altamont Capital Partners (ACP) for an undisclosed consideration.
Specialty Pharmacy Division is A-Med's specialty pharmacy division providing healthcare distribution services for patients with chronic diseases through home delivery.
Altamont Capital Partners is a private equity firm based in the San Francisco Bay area with over US$1 billion in capital, focused on investing in change-intensive middle market businesses. They are particularly drawn to companies which are constrained for some reason from realizing their full potential, and they seek opportunities to work in partnership with management to implement strategic and operational change. ACP is a generalist firm with deep experience in several verticals including business services, financial services, industrials, healthcare, technology, consumer, retail and aerospace & defense sectors.
A-Med Health Care provides healthcare distribution services for patients with chronic diseases through home delivery. A-Med's mission is to provide excellent care and achieve positive outcomes for its clients through comprehensive, cost effective, and quality services. Enhancing the health and well being of its clients promotes wellness. Utilization of available resources, consumer surveys, staff involvement, state and federal regulations, recognition of community and industry needs, technology, education, self evaluation, leadership, and financial stability will promote this mission.
Oaklins' team in Los Angeles advised the seller. This transaction was for the specialty pharmacy component of the business only. This transaction was for the specialty pharmacy component of the business only.
Talk to the deal team
Gary Rabishaw
Oaklins Intrepid
Eduard Bagdasarian
Oaklins Intrepid
Jeremiah Mann
Oaklins Intrepid
Related deals
Valmiermuižas Alus has been acquired by Cēsu Alus
Valmiermuižas Alus has been acquired by Cēsu Alus AS through the purchase of 100% of its shares. The transaction enabled the founder’s exit and strengthened the company’s platform for continued growth within a consolidating Baltic beverage market.
Learn moreLindenhofgruppe has sold its majority stake in LabPoint to Affidea Switzerland
LabPoint Medical Laboratories AG has been acquired by Affidea Switzerland AG. Through the transaction, Lindenhofgruppe AG gains a strong strategic partner to support the further development of LabPoint and will remain a shareholder with a reduced stake, continuing as a key customer of the company. It lays the foundation for LabPoint’s sustainable development under a new anchor shareholder, with the aim of further strengthening and selectively expanding its position in laboratory diagnostics.
Learn moreCapsol has been acquired by Angus Capital
Capsol has been acquired by Angus Capital as part of its strategy to build a leading construction services group alongside other portfolio companies. This partnership marks a new phase of growth for Capsol, providing the platform, resources and strategic support needed to accelerate its development and expand its market presence.
Learn more